Clinical data shows high efficacy and safety in Chinese patients with temple hollowing.
Galderma announced clinical trial results demonstrating that Restylane Volyme delivers high effectiveness, patient satisfaction, and a robust safety profile in Chinese patients with temple hollowing, according to multiple sources including BioSpace and Yahoo Finance. The study is significant because it establishes local clinical evidence in a key growth market and supports regulatory positioning in China.
Temple hollowing is a common aging concern in Asian populations and has become a standard indication for volume fillers in China. Restylane Volyme is a hyaluronic acid filler with a specific rheology profile optimized for mid-to-deep dermal placement and structural support. Clinical data published in regional markets often precedes expanded labeling or formulary inclusion.
Restylane Volyme shows high efficacy and safety in Chinese temple hollowing study.
For U.S. practice owners, this signals Galderma's continued investment in regional clinical evidence and suggests the company is building a global clinical narrative around Volyme's efficacy across diverse patient populations. This kind of localized data also supports pricing power and formulary negotiations in those markets.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
